HC Wainwright Reaffirms “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)

HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report released on Tuesday,Benzinga reports. The brokerage currently has a $16.00 price target on the biopharmaceutical company’s stock.

ESPR has been the subject of a number of other research reports. Needham & Company LLC cut their price objective on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Esperion Therapeutics Trading Up 2.0 %

Shares of ESPR stock opened at $2.52 on Tuesday. Esperion Therapeutics has a 1 year low of $1.16 and a 1 year high of $3.40. The firm’s fifty day simple moving average is $2.02 and its 200 day simple moving average is $2.15. The firm has a market capitalization of $496.53 million, a P/E ratio of -3.86 and a beta of 0.96.

Institutional Investors Weigh In On Esperion Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ESPR. BOKF NA bought a new stake in shares of Esperion Therapeutics during the second quarter worth $26,000. Xponance Inc. bought a new stake in Esperion Therapeutics during the 2nd quarter worth about $28,000. Traphagen Investment Advisors LLC bought a new position in shares of Esperion Therapeutics in the 3rd quarter valued at about $27,000. State Board of Administration of Florida Retirement System acquired a new stake in shares of Esperion Therapeutics during the 1st quarter worth approximately $50,000. Finally, National Bank of Canada FI raised its stake in shares of Esperion Therapeutics by 115.9% during the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 10,225 shares during the last quarter. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.